Page 18 - மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rubio s Bill to prevent China s access to US Genomic data

US Senator for Florida, Marco Rubio has introduced two bills to counter China efforts to collect US healthcare and genomics data both legally and illegally.

United statesMarco rubioJohn cornynHuman servicesNational institutes of healthCommittee on foreign investmentsSecurity centerSenate select committee on intelligenceSenate committee on intelligenceSenate committee on foreign relationsCommittee on foreign investmentClinical laboratory improvement amendmentsDepartment of healthSenate committee on healthEnhancement of national securityNational counter

Rubio s Bill to prevent China s access to US Genomic data

Rubio s Bill to prevent China s access to US Genomic data
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

United statesMarco rubioJohn cornynHuman servicesNational institutes of healthCommittee on foreign investmentsSecurity centerSenate select committee on intelligenceSenate committee on intelligenceSenate committee on foreign relationsCommittee on foreign investmentClinical laboratory improvement amendmentsDepartment of healthSenate committee on healthEnhancement of national securityNational counter

Rubio Unveils Bills Targeting China s Collection of Americans DNA

Rubio Unveils Bills Targeting China’s Collection of Americans’ DNA Sen. Marco Rubio (R-Fla.) has introduced two bills to counter the Chinese regime’s efforts to collect the genomic data of Americans through both legal and illegal means. The Republican senator, who has been a leading voice in addressing the issue, introduced the Genomics Expenditures and National Security Enhancement (GENE) Act and The Genomics Data Security Act on Thursday. Beijing has for years been collecting large amounts of American health care data, using illegal methods such as cyber hacking, investments in American biotech companies, and partnerships with hospitals and universities to gain access to the sensitive information.

United statesJohn cornynr texasHuman servicesNational institutes of healthSecurity centerSenate select committee on intelligenceSenate committee on foreign relationsCommittee on foreign investmentClinical laboratory improvement amendmentsNational counterintelligenceDepartment of healthNational security enhancementMarco rubioGenomics expendituresGenomics data security actJohn cornyn

Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting

/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced initial results from the CIRCULATE-Japan.

Kashiwa shiUnited statesSan carlosMike brophyTakayuki yoshinoKate stabrawaAlexey aleshinNatera incNational cancer center hospitalClinical laboratory improvement amendmentsAmerican society of clinical oncologyNational cancer centerDrug administrationClinical oncologyAnnual meetingPrincipal investigator

binx health requests EUA for CRISPR-based test for COVID-19

Industry News: binx health submits request for Emergency Use Authorization for first CRISPR-based point-of-care test for COVID-19 Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences 18 May 2021 binx health has announced the submission of an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the first CLIA-waived CRISPR-based point-of-care (POC) test for COVID-19. binx io is already the first CLIA-waived platform for the molecular detection of chlamydia and gonorrhea in about 30 minutes. binx has now adapted the single-use cartridge for analysis of RNA-based targets, pairing the high performance of Sherlock Biosciences’ proprietary CRISPR technology with binx’s rapid and sensitive proprietary electrochemical detection to create a powerful tool to help combat COVID-19. Data obtained in support of this authorization positions

Jeffrey luberSherlock biosciencesRahul dhandaSherlock bioscienceClinical laboratory improvement amendmentsDrug administrationIndustry newsEmergency use authorizationChief executiveOpen philanthropyChief executive officerSynthetic biologySpecific high sensitivity enzymatic reporterBinx health submits request for emergency use authorization first crispr based point of care test covid 19 diagnosticஜெஃப்ரி லூபர்ஷெர்லாக் உயிர் அறிவியல்